# Atrigel Technology: A Biodegradable Repository for Long-Term Drug Release

Swati Mahakul[1] Pranjul Shrivastava[2*], Dr. Sandip Prasad Tiwari[3]

[1,2,3]Faculty of Pharmacy Kalinga University Raipur, (C.G)

**Abstract:**

An important development in the realm of controlled drug release is the Atrigel® drug delivery system, which provides a flexible and biocompatible substrate for long-term parenteral drug administration. When injected into the body, the system, which was created utilizing a copolymer of poly(DL-lactide-co-glycolide) (PLGA) mixed in a biocompatible solvent such N-methyl-2-pyrrolidone (NMP), produces an in-situ solid depot. The quick phase inversion of this thermosensitive formulation causes polymer precipitation and the formation of a solid matrix that envelopes the medication. The medicine is released gradually and under control as the polymer degrades hydrolytically over time. This method provides exact control over medication pharmacokinetics without requiring surgical implantation. In clinical settings, the Atrigel system has been widely employed, especially for hormone therapy like leuprolide acetate (marketed as Eligard®), which is used to treat prostate cancer. Significant benefits of the technology include less systemic toxicity, decreased dose frequency, and enhanced patient compliance. Additionally, it may be tailored for a variety of therapeutic areas, such as infectious illnesses, psychiatry, and cancer, due to its adjustable release profiles, which range from a few days to several months. Enhancing the formulation's stability, expanding its usage to include protein and peptide medications, and boosting its drug-loading capability are the main goals of current research. Notwithstanding its advantages, research is still ongoing to address its drawbacks, which include initial burst release and solvent-related toxicity issues. Polymer chemistry and pharmaceutical sciences come together in the Atrigel system, and its continued advancement might expand the range of long-acting injectable treatments.

**Keywords:** Atrigel®, Drug Delivery System, Controlled Release, PLGA, In-Situ Forming Implants, Biodegradable Polymers, Sustained Release, Eligard®,Parenteral Drug Delivery, Phase Inversion, Thermosensitive Polymers, Polymer-Based Drug Delivery, Injectable Drug Systems, Targeted Therapy, Biodegradable Matrix, Long-Acting Formulations.

## INTRODUCTION:

The creation of new technologies is essential to improving the efficacy, safety, and patient compliance of therapeutic treatments in the constantly changing area of drug delivery systems.

Atrigel is a cutting-edge, biodegradable drug delivery method that has the potential to completely transform the way that drugs are taken, absorbed, and used by the body.

Atrigel is a biodegradable drug delivery system that regulates and maintains the release of pharmaceutical medications over long periods of time using a special technology. The Atrigel method was created mainly for injectable medication formulations and is intended to release a drug from a gel-like matrix gradually and precisely. It makes it possible for therapeutic substances to be sustained after a single dose, which lessens the need for regular dosage and increases patient compliance—especially when managing chronic conditions or long-term treatments. A biodegradable polymer that gels when injected into the body is the core of Atrigel's technology. A variety of medications, including small molecules, proteins, peptides, and biologics, can be encapsulated in this polymer system and released gradually over time in a regulated manner.

Atrigel's biocompatibility and biodegradability distinguish it from other drug delivery methods. Atrigel formulations provide a safer option to traditional medication carriers since the ingredients decompose naturally in the body over time without posing any risks. Its formulation versatility also makes it possible to incorporate a variety of medications, such as proteins, peptides, vaccines, and small molecules, making it a flexible platform for a range of therapeutic applications. Atrigel is in the vanguard of a new era in drug delivery technology, with potential in areas like immunology, cancer, and the management of chronic diseases, as the healthcare landscape continues to demand more effective, efficient, and patient-friendly therapies. This approach is changing not just how medications are administered but also how we envision medicine in the future.




**FIG. 1** – *Benefits of atrigel drug delivery system*

## 1.1 How Atrigel works: The Technology Behind It

Utilizing sophisticated polymer chemistry, the Atrigel system is a state-of-the-art, biodegradable drug delivery platform that permits the regulated and prolonged release of therapeutic medicines. Atrigel's technology is intended to solve a number of issues with conventional drug delivery techniques, including the requirement for regular dosage, the quick breakdown of medications, and systemic adverse effects. Here's a detailed breakdown of the technology behind Atrigel's operation.

***Composition of Atrigel system:***

The biodegradable polymer matrix at the center of the Atrigel system is in charge of encasing the active pharmaceutical ingredient (API) and regulating its release. Biodegradable substances like PCL (polycaprolactone), PLGA (polylactic-co-glycolic acid), and other biocompatible polymers are commonly used to create this polymer matrix.

- PLGA: One of the most often utilized biodegradable polymers in the Atrigel system is PLGA. It is preferred because when the body metabolizes it, it produces the non-toxic byproducts lactic acid and glycolic acid. Customized drug release patterns may be achieved by simply altering the ratio of lactic acid to glycolic acid, which alters the pace at which PLGA degrades.
- PCL: Another biodegradable polymer included in certain Atrigel formulations is polycaprolactone (PCL). PCL can be helpful when a longer time of drug release is needed since it degrades more slowly than PLGA.

***Transition from Injectable Liquid to Gel:***

The Atrigel system's capacity to change from a liquid to a gel after being injected into the body is one of its primary features. Temperature variations or the formulation's contact with physiological fluids (such the water in tissues) cause this liquid-to-gel phase shift.

- Liquid Formulation: A liquid solution is used to create the Atrigel formulation at first. The medicine (active medicinal component) is contained in this liquid together with the biodegradable polymer. Usually, a solvent that is safe for injection and compatible with the body is used to dissolve or suspend the medicine.
- Gelation Upon Injection: The liquid formulation comes into contact with the body's or the surrounding tissue fluid's warmer temperature when it is injected into the body. This alteration transforms the liquid into a gel-like material by causing the polymer to go through a solvent exchange or phase transition. The medicine is held in place and gradually released by the gel's solid-like network structure at the injection site.

## 1.2Advantages of Atrigel Drug Delivery System:

- **Sustained and Regulated Drug Release:** Depending on the formulation, Atrigel enables the precise, time-controlled release of medications over a period of days to months.

- **Enhanced Adherence by Patients:** Patients are more likely to follow their treatment plans when dose schedules are less frequent (weekly, monthly, or even quarterly).

- **Both biocompatible and biodegradable**: PLGA (poly(lactide-co-glycolide), a polymer used in Atrigel, safely breaks down into lactic acid and glycolic acid, which the body naturally metabolizes. Unlike several non-biodegradable delivery methods, there is no need to remove the implant surgically.

- **Localized and targeted delivery of atrigel:** The capacity of the Atrigel® drug delivery system to distribute medications locally and directly to the site of action is one of its most notable advantages. This benefit is essential in contemporary pharmacotherapy, where reducing systemic exposure while optimizing therapeutic impact is a primary objective, particularly in conditions like cancer, infections, or inflammation that call for high local drug concentrations.




**FIG.2 –** ***Atrigel Mechanism***

## 1.3Atrigel's Use in Medicine: Treating Chronic Illnesses

A biodegradable polymer (usually poly(D,L-lactide-co-glycolide), or PLGA) mixed in a biocompatible solvent such as N-methyl-2-pyrrolidone (NMP)) makes up the sustained-release medication delivery system Atrigel®. The polymer hardens and the solvent evaporates when the injection is administered to the body, creating an implant-like depot that distributes the medication gradually. Significant benefits are provided by this novel delivery system for the treatment of chronic conditions including diabetes, heart disease, and others.

- **Oncology: Using Atrigel in cancer therapies and chemotherapy:**

The most well-known application of Atrigel® in cancer treatment is in hormonal therapy for prostate cancer, particularly with the Eligard® product, which contains the gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate. Leuprolide inhibits testosterone synthesis, which is a major factor in the development of androgen-sensitive prostate cancers.

Eligard® comes in depot formulations for 1, 3, 4, and 6 months and is delivered by Atrigel®. Patients can skip frequent dosage while still receiving the medication at therapeutic levels thanks to its extended-release version.

- **Heart-related Conditions:**

Long-term medication therapy, such as statins, beta-blockers, and anticoagulants, is frequently used to treat cardiovascular problems. Here are some promising uses for Atrigel:

Long-Term Antihypertensive and Lipid-Lowering Therapy: Atrigel may be used to distribute medications in extended-release formulations, such as ACE inhibitors or statins, guaranteeing long-lasting therapeutic levels without the need for daily doses.

Better Patient Adherence: For patients with cardiovascular disease, non-compliance is a significant problem. Adherence is improved by a monthly or quarterly injection, especially for older patients or those experiencing cognitive impairment.

Post-Stent Drug administration: Atrigel might possibly be employed for localized, sustained administration of anti-restenosis medicines post-angioplasty or stent insertion, limiting systemic exposure and maximizing site-specific activity.

- **Other Potential Chronic Applications:**

Chronic Pain Management: For reliable pain treatment in diseases like cancer or arthritis, Atrigel can be used in conjunction with long-acting local anesthetics or opioids (such as bupivacaine or morphine).

Hormone Replacement Therapy: Long-acting testosterone or estrogen treatment can increase consistency and lessen adverse effects in situations like osteoporosis or hypogonadism.

Chronic Inflammatory Diseases: Atrigel can provide biologics or corticosteroids over an extended period of time, lowering flare-ups for illnesses like Crohn's disease or rheumatoid arthritis.

- **Gene Therapy & Biologics:**

At the vanguard of cutting-edge therapeutic approaches are gene therapy and biologic medications, such as proteins, peptides, and monoclonal antibodies. However, issues including instability, short half-life, repetitive dosage, and systemic adverse effects frequently restrict their practical application. A biodegradable, injectable in situ forming implant called the Atrigel® Drug Delivery System provides a solution by delivering these treatments locally and continuously. Applications in immunomodulation, biologics, and gene therapy may particularly benefit from this technology.

***Continuous Nucleic Acid Delivery:***

Plasmid DNA, mRNA, siRNA, or antisense oligonucleotides are frequently delivered as part of gene treatments; for best results, these materials need to be protected from degradation and released continuously. Therapeutic genes may be expressed locally and sustainably by encasing these nucleic acids in the PLGA matrix using Atrigel®. Long-term transgenic expression at the injection site has been achieved by the successful sustained release of plasmid DNA using PLGA-based delivery systems in experimental investigations (Mao et al., 2001). The identical PLGA/NMP basis used in Atrigel makes the results relevant even if not all investigations employed commercial Atrigel.

***CRISPR-Cas9 and Editing Genes:***

Recent research has concentrated on delivering CRISPR-Cas9 components, including as Cas9 mRNA/protein and guide RNAs, via PLGA-based systems, such as formulations that resemble Atrigel. To increase the effectiveness of gene editing in vivo, these materials need to be protected from nucleases and delivered via a gradual, sustained release mechanism.




**FIG.3 – *CRISPR based gene therapies***

## 1.4 Benefits of the Atrigel® Drug Delivery System Compared to Drug Delivery Systems Based on Nanoparticles:

As drug delivery technology have advanced, several systems have been created with the goal of enhancing patient compliance and therapeutic efficacy. Among these, nanoparticle-based drug delivery systems (NDDS) and the Atrigel® system have attracted a lot of interest. Although regulated and sustained drug release is provided by both systems, their methods, benefits, and drawbacks are different. This article highlights the special advantages of Atrigel over nanoparticles by comparing the Atrigel system with NDDS. Biodegradable polymers dissolved in a biocompatible solvent are used in the Atrigel system. The solvent evaporates during injection, enabling water to seep in and cause the polymer to precipitate, creating a solid depot at the injection site. Controlled drug release is made possible by this in situ gelation as the polymer matrix breaks down over time.

Drugs are encapsulated within nanoparticles, which can be designed for certain release patterns, in nanoparticle-based drug delivery systems, or NDDS. Both internal (such as pH, enzymes) and exterior (such as magnetic fields, light) stimuli can cause drug release.

## 1.5 Safety and Regulatory Aspects:

Regulatory bodies throughout the world have taken notice of the Atrigel® delivery system, a cutting-edge in situ gelling technology created by Atrix Laboratories (now a division of QLT Inc.). By using biodegradable polymers to create a gel at the injection site, this technique allows medicinal drugs to be released gradually and under control. Regulatory agencies including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have

assessed and authorized goods that use this technology, offering insights into their opinions on its efficacy, safety, and possible uses.

***FDA Approval of Products Based on Atrigel:***

The FDA has authorized a number of medications that use Atrigel technology, including as the prostate cancer Eligard® formulations. These products use a biodegradable polymer matrix to deliver leuprolide acetate, an agonist of luteinizing hormone-releasing hormone (LHRH). Clinical data proving the formulations' safety and effectiveness were thoroughly evaluated as part of the FDA's approval procedure for these medications.

Atrigel-based medicines have demonstrated in clinical trials that they may successfully reduce testosterone levels, a desirable pharmacological signal in the treatment of prostate cancer. In order to make sure that the drug release rates matched therapeutic goals, the FDA's evaluation also took into account the pharmacokinetic characteristics of these formulations.

***EMA's Strategy for Atrigel-Based Goods:***

Atrigel-based medications, like the Eligard® formulations, have also been assessed and authorized for use in Europe by the EMA. A thorough analysis of clinical trial data, including research on pharmacokinetics, pharmacodynamics, and safety profiles, is part of the EU approval procedure.

The significance of proving bioequivalence for generic formulations is emphasized in the EMA's recommendations. The government needs more information to prove bioequivalence in the case of intricate drug delivery systems like Atrigel. Pharmacokinetic research and, occasionally, pharmacodynamic evaluations may fall under this category.

## Obstacles and Things to Think About:

Complex medication delivery systems like Atrigel are difficult for the FDA and EMA to regulate. The variation in drug release patterns brought on by elements including injection site characteristics, drug load, and polymer composition is one major obstacle. To make sure that these factors don't compromise the product's safety and therapeutic efficacy, regulatory bodies need a lot of data. The long-term safety of biodegradable polymers is another factor to take into account. Although the body is meant to break down these elements, the byproducts of that breakdown must not be harmful or inflammatory. For regulatory bodies to evaluate the safety of these degradation products, thorough toxicological investigations are necessary.

The FDA and EMA's regulatory viewpoints on Atrigel-based devices demonstrate the difficulties in obtaining approval for sophisticated drug delivery systems. To make sure that these products are safe and effective for the purposes for which they are designed, both agencies need strong clinical evidence. Continuous cooperation between industry and regulatory agencies will be necessary as medication delivery technologies develop further in order to handle new issues and guarantee patient safety.

## 1.6The Future of Atrigel Drug Delivery Technology:

Atrigel® is an injectable, biodegradable, in situ gelling drug delivery method that allows therapeutic drugs to be released continuously by forming a depot after injection. The technology was initially created for hormone treatments such as Eligard® (leuprolide acetate), but it has shown great promise in a number of therapeutic domains. With an emphasis on innovations, new developments in biodegradable drug delivery, possible new therapeutic areas, and the function of Atrigel in personalized medicine, this study examines the future of Atrigel systems.

**Future Developments and Advancement:**

### 1. Advanced Engineering of Materials:

In order to improve biocompatibility and functionality, future advancements in Atrigel technology may use cutting-edge materials like biohybrid polymers, which combine synthetic and natural components. Furthermore, more accurate control over drug administration may be possible with the use of stimuli-responsive polymers, which release medications in reaction to particular physiological changes, such as pH, temperature, or the presence of enzymes.

### 2. Machine Learning and Artificial Intelligence (AI):

Biodegradable system development is being revolutionized by AI-driven design. Predictive algorithms can improve material compositions for particular treatment demands and simulate drug release characteristics. By figuring out the best doses and release rates depending on each patient's unique profile, AI also makes it easier to create customized medication delivery systems.

### 3. Improved Production Methods:

Complex, patient-specific medication delivery devices may be created because to advancements in manufacturing techniques like 3D bioprinting. With the use of this technology, scaffolds and implantable devices that replicate certain tissues or biological processes may be created, providing scalable, intricate disease therapies.

**Atrigel's Function in Precision Healthcare and Personalized Medicine:**

### 1.Customized Medication Administration:

Atrigel systems may be tailored to release medications according to the genetic profiles, illness stages, and metabolism rates of specific patients. Patients are guaranteed to receive the best care possible with the fewest possible adverse effects thanks to this individualized approach.

### 2.Monitoring and Modification in Real Time:

Real-time patient reaction monitoring is made possible by the combination of sensors and digital health technologies with Atrigel devices. This feature maximizes therapeutic results by allowing medical professionals to quickly modify treatment strategies.

**3. The patient-centered method:**

By offering therapies that are customized to meet their individual needs, personalized medication delivery systems empower patients. This method improves adherence, patient comfort, and general treatment satisfaction.

Innovations in material science, artificial intelligence, and digital health integration are expected to propel major breakthroughs in Atrigel drug delivery technology in the future. These advancements have the potential to broaden the therapeutic uses of Atrigel systems, namely in the fields of gene therapy, neurological diseases, and cancer. A new age in precision healthcare is being ushered in by Atrigel technology, which is in line with the tenets of customized medicine and provides a route to more efficient, patient-centered therapies.




**FIG- 4:** ***comparative study of atrigel with traditional gel solutions***

**Conclusion:**

An important development in the realm of regulated and sustained medication release is the Atrigel® drug delivery technology. Atrigel was created in 1987 by Dunn and associates and uses biodegradable polymers that have been dissolved in biocompatible solvents. When the medicine is injected, the system forms a gel that wraps it and releases it gradually as the polymer breaks

down**.** Atrigel has transformed medication delivery by fusing the benefits of microparticles with solid implants. While microparticles frequently encounter difficulties including complicated production procedures and batch-to-batch variability, traditional solid implants must be surgically implanted. By providing an injectable system that solidifies into an implant when it comes into touch with bodily fluids, Atrigel gets over these restrictions and offers continuous medication release without requiring surgery. For medications that need delayed release profiles or have low bioavailability, this method has increased the therapeutic options. Its use in the treatment of long-term illnesses including cancer and hormone imbalances has enhanced therapeutic results and patient compliance. Biodegradable drug delivery technologies are becoming more and more popular in the pharmaceutical business worldwide because of their favorable patient profiles and lower environmental effect. With its distinct in situ gelation process, Atrigel is well-positioned to be a key player in this shift. Even though Atrigel has many benefits, there are also issues, such the requirement for lengthy clinical studies and regulatory licenses. Nonetheless, there are a lot of chances for the broad use of Atrigel-based systems due to the growing need for individualized medicine and the move toward patient-centered treatment alternatives. By offering a flexible, minimally invasive, and reasonably priced method for long-term drug release, Atrigel has made substantial progress in the field of drug delivery. Its capacity to deliver medications directly to the target location and its compatibility with a broad variety of therapeutic agents have revolutionized therapy paradigms, especially for complicated and chronic illnesses. Atrigel and other biodegradable drug delivery technologies are anticipated to be vital in determining the direction of healthcare in the future as the pharmaceutical industry continues to place a high priority on patient-centric solutions.

**References:**


1. Verma RK et al. (2016). *A Review on Atrigel: A Novel Drug Delivery System Forming Implants.* Academia.edu
2. Jain RA (2000). *The manufacturing techniques of various drug-loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.* Biomaterials
3. Scott LJ (2018). *Sufentanil sublingual tablet system: A review in moderate to severe acute pain.* Drugs
4. Ringe JD et al. (2011). *Routine treatment with Eligard for prostate cancer: safety and efficacy in a real-world study.* BMC Urology
5. Dunn RL, et al. (2004). *Atrigel drug delivery system*. In: Wise DL (Ed.), Handbook of Pharmaceutical Controlled Release Technology. CRC Press. Link to publisher4
6. Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2020). Injectable mesoporous silica hydrogel for controlled delivery of vaccines. *ACS Central Science*, 6(1), 150–159. Link
7. Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., ... & Loré, K. (2021). Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. *Science Translational Medicine*, 13(582). Link

8. Schweizer, M.T., Antonarakis, E.S. (2015). Hormonal therapy in prostate cancer: historical approaches and current clinical applications. *European Urology*, 68(5), 876–887.
9. Bhalerao K, Patil S, Patil S, et al. A review on Atrigel: A novel drug delivery system forming implants. World J Pharm Res. 2015;4(11):135-145.